Rapamycin (Sirolimus) and Levothyroxine Interaction: Safety, Monitoring, and Dosing Guidance

Rapamycin is the common name for sirolimus (brand name Rapamune), an mTOR inhibitor approved by the FDA for prophylaxis of organ transplant rejection and used off-label in lower, intermittent doses in some longevity-focused protocols. Levothyroxine (brand names Synthroid, Levoxyl, Tirosint, and others) is a synthetic form of thyroxine (T4) used to treat hypothyroidism. This article covers the interaction between oral sirolimus and oral levothyroxine specifically, not sirolimus-coated stents or other mTOR inhibitors such as everolimus or temsirolimus.

The direct answer

Sirolimus and levothyroxine are not classified as contraindicated. Major interaction references (Lexicomp, Micromedex) place this pairing at a moderate, "monitor therapy" level rather than a major or avoid-combination level. The interaction is pharmacokinetic and one-directional: sirolimus and its tablet excipients may interfere with levothyroxine absorption if taken close together, but levothyroxine has no known effect on sirolimus blood levels because it is not metabolized through CYP3A4 or transported by P-glycoprotein, the two pathways that govern sirolimus exposure. The standard mitigation is timing separation of at least several hours plus periodic TSH monitoring, not dose contraindication.

Why this pairing comes up often

Patients on sirolimus for transplant rejection prophylaxis frequently have or develop hypothyroidism requiring levothyroxine. Post-transplant thyroid dysfunction is a recognized clinical issue, though the exact prevalence figures vary across cohorts and require verification against the specific transplant population and immunosuppressive regimen used. Patients taking sirolimus off-label in intermittent, lower-dose longevity protocols may also be on levothyroxine for unrelated, pre-existing hypothyroidism.

Mechanism: absorption competition, not shared metabolism

Levothyroxine requires an acidic gastric environment and an empty stomach for reliable dissolution and jejunal uptake. The FDA-approved levothyroxine label lists a number of agents known to reduce its bioavailability when taken close in time, including calcium, iron, proton pump inhibitors, and bile acid sequestrants. Sirolimus is not on that specific list, but the mechanism of competing for absorption in the same segment of gut, and the presence of tablet excipients (lactose, sucrose, and other binders) in the same intestinal window, is pharmacologically plausible as a source of reduced levothyroxine uptake.

The sirolimus prescribing information notes that high-fat meals increase sirolimus absorption; exact percentage changes in Cmax and AUC should be confirmed against the current label text rather than assumed, since label versions and reported figures can differ. Because sirolimus is often dosed with food while levothyroxine must be dosed fasting, the two drugs naturally push toward different times of day, which is itself a partial built-in mitigation if patients follow standard administration instructions for each drug independently.

There is no direct enzyme competition between the two drugs. Levothyroxine is cleared mainly through deiodination and conjugation (glucuronidation, sulfation), not CYP450 metabolism. Sirolimus is extensively metabolized by CYP3A4 and is a P-glycoprotein substrate. Because levothyroxine does not meaningfully inhibit or induce either pathway, there is no established mechanism for levothyroxine to change sirolimus blood levels.

Does sirolimus affect thyroid function on its own?

Separate from the absorption question, mTOR inhibition affects immune regulation, including T-cell pathways involved in tolerance. Case reports and small transplant-cohort studies have described new-onset thyroid autoimmunity (positive anti-thyroid peroxidase antibodies) in some patients after starting sirolimus or converting from a calcineurin inhibitor to sirolimus. This is biologically plausible and has clinical support in the transplant literature, but a precise incidence figure for this specific event is not something this article can confirm without checking the original cohort study, and any number quoted for it should be treated as unverified until sourced directly.

Sirolimus is also associated with dyslipidemia (elevated total cholesterol and triglycerides) in a meaningful proportion of patients. Significant lipid elevation can alter binding of thyroid hormone to carrier proteins (thyroid-binding globulin, transthyretin), which in turn can affect total T4 measurements. Free T4 and TSH remain the preferred tests for monitoring thyroid status in patients with abnormal lipid profiles; in cases of extreme triglyceride elevation, some clinicians use equilibrium dialysis-based free T4 assays to avoid protein-binding artifact, consistent with general endocrinology practice for patients with binding-protein abnormalities.

Evidence-status map for this interaction

What this means for dosing and timing

Because the interaction is about absorption timing rather than a fixed pharmacokinetic penalty, the practical approach does not require a precise numeric offset beyond standard levothyroxine administration guidance: take levothyroxine first thing in the morning on an empty stomach, and wait at least 30 to 60 minutes before eating or taking other medications, as instructed on the levothyroxine label. Take sirolimus at a different time of day, consistently with or without food according to its own instructions, rather than immediately adjacent to the levothyroxine dose.

For once-weekly, low-dose sirolimus regimens used in some off-label longevity protocols, this separation is easy to achieve: levothyroxine is taken daily in the morning as usual, and the weekly sirolimus dose is taken later in the day, ideally with a meal per the label's food guidance.

For daily sirolimus regimens used in transplant care, a morning-levothyroxine, evening-sirolimus pattern is a reasonable default, though the actual sirolimus dosing schedule in transplant patients is set by the transplant team based on trough-level targets and should not be changed without their input.

Do not crush, split, or combine either medication into the same dose. Liquid or gel-cap levothyroxine formulations (such as Tirosint or Tirosint-SOL) contain fewer excipients and may reduce absorption variability in patients on multiple interacting medications, but this is a formulation consideration for the prescriber to weigh, not a substitute for dose separation.

Monitoring after starting or changing either drug

A reasonable, non-drug-specific approach follows standard levothyroxine monitoring practice:

• Before adding the second drug, if not already done: baseline TSH, free T4, and (in transplant patients) sirolimus trough level.
• Roughly 6 to 8 weeks after starting or changing either drug: recheck TSH and free T4. This interval reflects the time needed for TSH to re-equilibrate after a change in thyroid hormone availability, a standard principle in levothyroxine management rather than a rule specific to sirolimus.
• If TSH has moved outside the patient's target range, a levothyroxine dose adjustment (typically in small increments) may be needed; adjustments should be made by the prescribing clinician based on the individual's target TSH, age, and cardiac history, not from a generic table.
• In patients with significant dyslipidemia, confirm thyroid status with free T4 and TSH rather than total T4, and consider equilibrium dialysis-based free T4 if lipid elevation is extreme.
• In transplant patients, any levothyroxine timing change should be flagged to the transplant team so a sirolimus trough level can be rechecked if timing shifts affect their overall medication schedule.

Special populations that need closer attention

Post-transplant patients carry the highest stakes because both sirolimus and levothyroxine have narrow therapeutic or target ranges in this group, and this population also commonly takes other absorption-interfering drugs (proton pump inhibitors, phosphate binders, iron). Coordination with the transplant team on both drugs is appropriate rather than adjusting either independently.

Patients with thyroid cancer on TSH-suppressive levothyroxine doses have the least margin for any reduction in levothyroxine absorption, since even a modest bioavailability loss can allow TSH to rise above a suppressive target. Closer-interval TSH checks after starting sirolimus are reasonable for this group, at a frequency set by the treating endocrinologist.

Patients on off-label, intermittent low-dose sirolimus for longevity purposes generally have fewer competing medications and more flexibility in timing, which makes simple dose separation easier to achieve. Evidence for rapamycin's use in longevity contexts, including ongoing human trials, can be reviewed through public trial registries such as ClinicalTrials.gov; this article does not attempt to characterize any specific trial's design or eligibility criteria without a verified primary source.

What is not established

No published controlled pharmacokinetic study of the sirolimus-levothyroxine pair specifically was located to support a numeric estimate of how much levothyroxine absorption is reduced by co-administration, nor a validated incidence rate for sirolimus-induced thyroid autoimmunity that can be cited with confidence in this draft. Any percentage figures previously circulated for this pairing should be treated as unverified until checked against a primary source, and a pharmacist or endocrinologist should be consulted before making dosing decisions based on such figures. This is a gap the medical reviewer should close before publication if a suitable citation exists.

When to seek urgent care

New or worsening symptoms of significant hypothyroidism (severe fatigue, confusion, marked cold intolerance, swelling, slowed heart rate) or symptoms of thyroid hormone excess (rapid heartbeat, chest pain, significant tremor) after a dose change warrant prompt contact with the prescribing clinician, and severe symptoms such as chest pain, fainting, or altered mental status warrant emergency evaluation. Transplant patients with any concern about missed or altered sirolimus dosing should contact their transplant team directly rather than adjusting the regimen on their own.

Other sirolimus interactions worth knowing about

The interactions that carry the most immediate risk with sirolimus are pharmacokinetic ones involving CYP3A4: strong inhibitors (such as ketoconazole, itraconazole, clarithromycin, and grapefruit juice) can raise sirolimus blood levels substantially, and strong inducers (such as rifampin, phenytoin, and carbamazepine) can lower them, per the sirolimus FDA label. These are higher-priority interactions to manage than the levothyroxine pairing, which is absorption-based rather than metabolic. Separately, calcium, iron, proton pump inhibitors, and bile acid sequestrants each independently reduce levothyroxine absorption and can compound any sirolimus-related timing issue if a patient is on several of these at once.

This article is drafted for editorial and qualified medical review and has not yet received that review. Several claims in the source material could not be verified against a primary study and have been narrowed or flagged above; a clinician or pharmacist with access to the original literature should confirm any numeric claims before this page is published.